Levosimendan Tillomed

Levosimendan, the active ingredient in Levosimendan Tillomed, is a calcium sensitizer presented as an intravenous solution for intravenous use. It is indicated for the treatment of acute decompensated heart failure in adult patients. GNH USA supplies Levosimendan Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Levosimendan acts on the cardiovascular system to improve cardiac performance in acute heart failure settings.

Acute decompensated heart failure: enhances cardiac output and relieves pulmonary congestion. Severe left ventricular systolic dysfunction: increases contractility without raising intracellular calcium. Low‑output syndrome after cardiac surgery: supports hemodynamics while reducing afterload. Cardiogenic shock (selected cases): provides inotropic support with vasodilatory effect.

Levosimendan may be associated with several adverse reactions that clinicians monitor during therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea or vomiting: transient gastrointestinal upset. - Hypotension: reduction in blood pressure, especially with rapid infusion. - Tachycardia: increased heart rate. - Flushing: warmth and redness of the skin.

Serious or Rare Side Effects: - Arrhythmias: ventricular or atrial ectopic beats. - Severe hypotension: may require vasopressor support. - Myocardial ischemia: chest pain or ECG changes. - Allergic reactions: rash, pruritus, or anaphylaxis. - Electrolyte disturbances: especially hypokalemia.

When prescribing Levosimendan, consider the following safety measures.

Renal impairment: adjust monitoring as clearance may be reduced. Hepatic dysfunction: observe for prolonged drug exposure. Hypotension risk: avoid rapid bolus administration. Concomitant vasodilators: monitor blood pressure closely. Pregnancy and lactation: use only if benefits outweigh potential risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with other cardiovascular agents; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations. - Concurrent use with other potent vasodilators (e.g., nitroprusside): risk of severe hypotension.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt desired inotropic effect. - Diuretics: can exacerbate electrolyte imbalances. - ACE inhibitors or ARBs: additive blood pressure lowering effect.